Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Nov 27;6(48):eabc8733. doi: 10.1126/sciadv.abc8733

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC).

This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial license, which permits use, distribution, and reproduction in any medium, so long as the resultant use is not for commercial advantage and provided the original work is properly cited.

PMC Copyright notice

Fig. 5 — (A) The fluorescent emission spectrum of Ag₂S@Fe₂C and Ag₂S@Fe₂C-DSPE-PEG-iRGD in NIR-II under the excitation of 808-nm laser. (B) Real-time NIR-II fluorescence images of 4T1 breast cancer–bearing mice after intravenous injection of Ag₂S@Fe₂C-DSPE-PEG and Ag₂S@Fe₂C-DSPE-PEG-iRGD. Ex vivo fluorescence images of heart (i), kidney (ii), spleen (iii), liver (iv), lung (v), and tumor (vi), which were obtained at 48 hours after injection. Photo credit: Zhiyi Wang, Peking University, China. (C) The fluorescence intensities of the tumor after intravenous injection of Ag₂S@Fe₂C-DSPE-PEG and Ag₂S@Fe₂C-DSPE-PEG-iRGD, respectively. (D) T₂ relaxation rate (1/T₂) as a function of Fe concentration for the Ag₂S@Fe₂C-DSPE-PEG-iRGD. (E) Real-time MRI of 4T1 breast cancer–bearing mice after intravenous injection of Ag₂S@Fe₂C-DSPE-PEG and Ag₂S@Fe₂C-DSPE-PEG-iRGD. (F) The relative MRI signal intensities changing at the tumor site after intravenous injection of Ag₂S@Fe₂C-DSPE-PEG and Ag₂S@Fe₂C-DSPE-PEG-iRGD, respectively. (G) The wide-field images show the Ag₂S@Fe₂C-DSPE-PEG-iRGD luminescence signals in liver and spleen at 1 and 14 days. (H) The excretion of Ag₂S@Fe₂C-DSPE-PEG-iRGD from mouse liver and spleen can be seen by plotting the signal intensity in these organs (normalized to liver signal observed at 1 day) as a function of time over 2 weeks. (I) Biodistribution of Ag₂S@Fe₂C-DSPE-PEG-iRGD in main organs and feces of Ag₂S@Fe₂C-DSPE-PEG-iRGD–treated mice at 14 days. Error bars, means ± SD (n = 3).